The Private BankerSaturday, November 21, 2026

Pfizer Lifts 2026 Revenue Forecast by $1.5 Billion at the Midpoint as Eliquis Sales Jump 25% and Covid Products Slump

Third-quarter revenue of $16.58 billion beat the $15.87 billion consensus, but flat sales and a $650 million Innovent charge left reported earnings per share down 9%.

Bottles on shelves inside a laboratory
Photo by Nishant Aneja on Pexels.com

Pfizer raised its 2026 revenue forecast to $62.0 billion to $64.0 billion from $60.5 billion to $62.5 billion on Tuesday, after third-quarter sales of $16.58 billion topped the $15.87 billion analysts expected and adjusted earnings of 87 cents a share beat the 73 cents forecast.

The drugmaker also lifted its adjusted earnings-per-share range to $2.95 to $3.05 from $2.80 to $3.00, narrowing the band. The new range absorbs a one-time $650 million acquired research charge tied to the in-licensing deal with Innovent Biologics, which cuts roughly 10 cents from per-share earnings.

Revenue was little changed from a year earlier, down $71 million, as lower Covid sales offset growth elsewhere. Sales excluding Comirnaty and Paxlovid rose 7% on an operational basis, and products launched or acquired in recent years climbed 32% to about $3.8 billion.

The blood thinner Eliquis led the gains with $2.52 billion in sales, up 25% and ahead of the $2.40 billion consensus. Part of the increase reflects U.S. pricing dynamics rather than volume alone. The cancer drug Padcev rose 55% to $720 million, against $658 million expected. Lorbrena gained 43%, Nurtec 33% and the Vyndaqel family 12%.

Covid products continued to shrink. Paxlovid sales fell 63% to $449 million, a $771 million drop, while Comirnaty slid 29% to $808 million. Both still beat estimates of $394 million and $770 million. Pfizer reaffirmed its outlook for about $4 billion of Covid product revenue this year, with most vaccine sales expected in the fourth quarter. Prevnar sales fell 10%.

Reported diluted earnings were 56 cents a share, down from 62 cents a year earlier, with net income of $3.24 billion compared with $3.54 billion. Adjusted earnings of 87 cents were unchanged from the same quarter in 2025.

The year-to-date picture is weaker than the headline raise suggests. Nine-month revenue of $46.07 billion is up 2%, but adjusted earnings of $2.39 a share are 7% lower than a year ago and reported earnings of 99 cents are down 40% from $1.65.

The low end of the new revenue range sits at or slightly below the $62.6 billion Pfizer booked in 2025, so the guidance implies a flat-to-modest-growth year. The forecast assumes about $1.1 billion of revenue lost to generic and biosimilar competition, excludes business-development deals not yet closed, and assumes no share repurchases in 2026 and about 5.74 billion diluted shares.

Costs are also moving higher. Pfizer raised its adjusted research and development expense range to $10.8 billion to $11.8 billion from $10.5 billion to $11.5 billion, and set selling, informational and administrative expenses at $12.5 billion to $13.5 billion. Its net cost-savings target through 2029 was lifted to about $9.7 billion.

Cecile Guegan took over as chief financial officer on Nov. 1. She had been interim CFO since August, when Dave Denton left to become finance chief at Nike.

Pipeline updates came alongside the numbers. Elrexfio met its progression-free survival endpoint at an interim analysis of the Phase 3 MagnetisMM-32 study, the Phase 2 atopic dermatitis candidate tilrekimig hit its primary endpoint, and the European Medicines Agency validated the marketing application for Pfizer’s Lyme disease vaccine in August. The FDA approved the 2026-2027 Comirnaty formula targeting the XFG variant.

Pfizer put about $850 million into business development over the first nine months, most of it for the Innovent agreement.

Sources: pfizer.com, CNBC, Yahoo Finance, Bloomberg.